Sagent Pharmaceuticals (SGNT)
Sagent Pharmaceuticals Market Cap: 445.52M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SGNT Market Cap Rankings
| Overall | 47th percentile | 2458 of 4665 |
| Sector | 60th percentile | 206 of 527 in Healthcare |
| Industry | 50th percentile | 7 of 14 in Drugs - Generic |
SGNT Market Cap Range, Past 5 Years
| Minimum | 445.52M | Jun 1 2012 |
| Maximum | 750.85M | Jun 2011 |
| Average | 568.83M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these SGNT related companies
SGNT News
Sagent Pharmaceuticals Announces Launch of Atracurium Besylate Injection, USP
May 18, 9:00AM GlobeNewswire
May 18, 9:00AM GlobeNewswire
UPDATE: Morgan Stanley Cuts PT to $27 on Sagent Pharmaceuticals; Progress Amid Soft Q1
May 14, 7:40AM Benzinga
May 14, 7:40AM Benzinga
$SGNT forms bearish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3nTk
about 21 days ago by RecogniaEvents
about 21 days ago by RecogniaEvents
Needham & Company Maintains a 'Hold' on Sagent Pharmaceuticals (SGNT); Results On the Short Side of Expectations
May 11, 8:51AM Street Insider
May 11, 8:51AM Street Insider
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2012 Financial Results
Apr 27, 4:00PM GlobeNewswire
Apr 27, 4:00PM GlobeNewswire
$SGNT forms bearish "Continuation Wedge" chart pattern. http://stks.co/36jn
about 66 days ago by RecogniaEvents
about 66 days ago by RecogniaEvents
$SGNT Insider Sale: $1.9M of stock sold between February 15, 2012 - February 17, 2012 http://stks.co/2T49
about 105 days ago by MarketBrief
about 105 days ago by MarketBrief
Needham & Company Maintains a 'Hold' on Sagent Pharmaceuticals (SGNT); Impressive Q4, But Shares Fairly Valued
Feb 17, 9:21AM Street Insider
Feb 17, 9:21AM Street Insider
Listen to $SGNT Q4 2011 earnings call (EPS -0.33 vs est -0.114) - live at 10:00 AM, ondemand after - http://stks.co/2RQY
about 106 days ago by earningscast
about 106 days ago by earningscast
Sagent Pharmaceuticals, Inc. (SGNT) Reports Q4 Loss of $0.33, Offers FY12 Sales Guidance
Feb 16, 8:08AM Street Insider
Feb 16, 8:08AM Street Insider
Sagent Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Feb 16, 8:00AM GlobeNewswire
Feb 16, 8:00AM GlobeNewswire
$SGNT Insider Sale: $1.1M of stock sold between January 30, 2012 - February 1, 2012 http://stks.co/2DyQ
about 120 days ago by MarketBrief
about 120 days ago by MarketBrief
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2011 Financial Results
Feb 02, 4:00PM GlobeNewswire
Feb 02, 4:00PM GlobeNewswire
$SGNT Insider Sale: $1.1M of stock sold between January 30, 2012 - February 1, 2012 http://stks.co/2CV3
about 121 days ago by MarketBrief
about 121 days ago by MarketBrief
$SGNT Insider Sale: $2.1M of stock sold between January 11, 2012 - January 12, 2012 http://stks.co/1vWK
about 140 days ago by MarketBrief
about 140 days ago by MarketBrief
Sagent Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Jan 04, 10:15AM GlobeNewswire
Jan 04, 10:15AM GlobeNewswire
Collins Stewart Starts Sagent Pharmaceuticals (SGNT) at Buy; Potential Earnings Upside is Underappreciated
Nov 29, 7:28AM Street Insider
Nov 29, 7:28AM Street Insider
Sagent to benefit from President Obama's executive order, says Jefferies
Nov 01, 7:27AM FlyOnTheWall
Nov 01, 7:27AM FlyOnTheWall
Sagent Pharmaceuticals (SGNT) To Benefit From Obama's Executive Order - Jefferies
Nov 01, 7:11AM Street Insider
Nov 01, 7:11AM Street Insider
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2011 Financial Results
Oct 27, 8:00AM GlobeNewswire
Oct 27, 8:00AM GlobeNewswire
Sagent Pharma announces FDA approval of Bupivacaine Hydrochloride injection
Oct 20, 8:03AM FlyOnTheWall
Oct 20, 8:03AM FlyOnTheWall
Sagent Pharmaceuticals Announces U.S. FDA Approval of Bupivacaine Hydrochloride Injection, USP
Oct 20, 8:00AM GlobeNewswire
Oct 20, 8:00AM GlobeNewswire
Sagent Pharmaceuticals Announces FDA Approval of Clindamycin Injection, USP
Sep 30, 4:24PM GlobeNewswire
Sep 30, 4:24PM GlobeNewswire
J.P. Morgan Initiates Coverage on Sagent Pharmaceuticals with a Neutral Rating
Sep 28, 7:35AM Benzinga
Sep 28, 7:35AM Benzinga
$SGNT
Sagent Pharmaceuticals Names Jonathon Singer Chief Financial Officer
about 281 days ago by Benzinga
about 281 days ago by Benzinga
RT @IPOtweet US IPO market pushes ahead; 5/6 IPOs post positive returns this week $VNET $MKTG $SGNT $TLLP $MNEL $AL http://bit.ly/fQeAA5
about 405 days ago by alphatrends
about 405 days ago by alphatrends
Sagent Pharmaceuticals $SGNT IPO open. Shares trading at $18.50 after pricing at $16
about 408 days ago by Street_Insider
about 408 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SGNT | 15.98 | +0.03 | +0.19% | 444.69M |
| SGMS | 8.20 | -0.34 | -3.98% | 790.29M |
| SGMO | 4.23 | -0.21 | -4.73% | 233.37M |
| SGMA | 3.77 | -0.03 | -0.79% | 14.86M |
| SGK | 10.66 | -0.49 | -4.39% | 287.22M |
| SGI | 5.55 | -0.34 | -5.77% | 186.36M |
| SGGG | 58.88 | -0.97 | -1.62% | |
| VE | 11.20 | -0.26 | -2.23% | 5.792B |
| VDSI | 6.85 | -0.14 | -2.00% | 267.37M |
| VDE | 90.26 | -2.27 | -2.45% |
